Acer Therapeutics Inc. Business Finance Contracts & Agreements
79 Contracts & Agreements
- Credit Agreements (7 contracts)
- Exchange Agreements (1)
- Guarantee Agreements (1)
- Loan Agreements (2)
- Note Agreements (12)
- Purchase Agreements (10)
- Registration Rights Agreements (5)
- Release Agreements (1)
- Security Agreements (4)
- Stock Agreements (10)
- Subscription Agreements (6)
- Underwriting Agreements (6)
- Waiver Agreements (2)
- Warrant Agreements (12)
- Amendment No. 1 to Unsecured Promissory Note dated as of August 30, 2023 by and between Acer Therapeutics Inc. and Christopher Schelling (Filed With SEC on August 31, 2023)
- Security Agreement dated as of August 30, 2023 by and between Zevra Therapeutics, Inc. and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Bridge Loan Agreement dated as of August 30, 2023 by and between Zevra Therapeutics, Inc. and Acer Therapeutics Inc (Filed With SEC on August 31, 2023)
- Warrant issued on June 16, 2023, by the Company to SWK Funding LLC (Filed With SEC on August 14, 2023)
- Unsecured Promissory Note, dated as of June 22, 2023, between Acer Therapeutics Inc. and Christopher Schelling (Filed With SEC on June 26, 2023)
- Form of Securities Purchase Agreement, dated as of March 21, 2023, between Acer Therapeutics Inc. and the Purchaser (Filed With SEC on March 22, 2023)
- Form of Common Stock Purchase Warrant (Filed With SEC on March 22, 2023)
- Form of Pre-Funded Common Stock Purchase Warrant (Filed With SEC on March 22, 2023)
- Amendment Agreement dated January 30, 2023, with respect to Secured Convertible Note Purchase Agreement between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare... (Filed With SEC on January 31, 2023)
- Warrant issued on January 30, 2023, by the Company to SWK Funding LLC pursuant to the Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc.,... (Filed With SEC on January 31, 2023)
- Second Amendment to Credit Agreement dated January 30, 2023, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole... (Filed With SEC on January 31, 2023)
- Securities Purchase Agreement, dated November 29, 2022, by and between Acer Therapeutics Inc. and the investors listed on Schedule I thereto (Filed With SEC on November 30, 2022)
- Warrant issued on August 19, 2022, by the Company to SWK Funding LLC pursuant to the Amendment to Credit Agreement dated August 19, 2022, among Acer Therapeutics Inc., the lenders... (Filed With SEC on August 23, 2022)
- Amendment to Credit Agreement dated August 19, 2022, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole... (Filed With SEC on August 23, 2022)
- Form of Guarantee and Collateral Agreement to be dated the Term Loan Funding Date among Acer Therapeutics Inc. and MAM Aardvark, LLC, as agent (Filed With SEC on March 7, 2022)
- Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto and MAM Aardvark, LLC, as the agent, sole lead arranger and sole bookrunner (Filed With SEC on March 7, 2022)
- Form of Secured Convertible Note issuable by Acer Therapeutics Inc. to MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P. pursuant to the Secured Convertible Note... (Filed With SEC on March 7, 2022)
- Secured Convertible Note Purchase Agreement dated March 4, 2022, between Acer Therapeutics Inc., MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P (Filed With SEC on March 7, 2022)
- Warrant issued on March 4, 2022, by the Company to SWK Funding LLC pursuant to the Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto... (Filed With SEC on March 7, 2022)
- Guarantee and Collateral Agreement dated March 4, 2022, among Acer Therapeutics Inc. and SWK Funding LLC, as agent (Filed With SEC on March 7, 2022)
- Credit Agreement dated March 4, 2022, among Acer Therapeutics Inc., the lenders party thereto and SWK Funding LLC, as the agent, sole lead arranger and sole bookrunner (Filed With SEC on March 7, 2022)
- Waiver and Agreement, dated October 6, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on October 8, 2021)
- Security Agreement, dated January 25, 2021, by and between Acer Therapeutics Inc. and Relief Therapeutics Holding AG (Filed With SEC on January 25, 2021)
- Promissory Note, dated January 25, 2021, issued by Acer Therapeutics Inc. in favor of Relief Therapeutics Holding AG (Filed With SEC on January 25, 2021)
- Securities Purchase Agreement, dated July 24, 2020, by and between Acer Therapeutics Inc. and the investors listed on Schedule I thereto (Filed With SEC on July 27, 2020)
- Registration Rights Agreement, dated as of April 30, 2020 by and between Acer Therapeutics Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 30, 2020)
- Purchase Agreement, dated as of April 30, 2020 by and between Acer Therapeutics Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on April 30, 2020)
- Description of the Companys capital stock registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 18, 2020)
- Underwriting Agreement, dated August 1, 2018, by and among Acer Therapeutics Inc. and William Blair & Company, L.L.C. and Raymond James & Associates, Inc., as representatives of... (Filed With SEC on August 1, 2018)
- Specimen common stock certificate (Filed With SEC on May 15, 2018)
- Underwriting Agreement, dated December 12, 2017, by and between Acer Therapeutics Inc. and William Blair & Company, L.L.C., as Representative of the several underwriters (Filed With SEC on December 12, 2017)
- Specimen common stock certificate (Filed With SEC on November 13, 2017)
- SUBSCRIPTION AGREEMENT (Filed With SEC on July 19, 2017)
- OPEXA THERAPEUTICS, INC. DOCS® ATM financing facility Shares of Common Stock, $0.01 par value SALES AGREEMENT March 25, 2016 (Filed With SEC on March 25, 2016)
- AMENDMENT TO STOCK PURCHASE AGREEMENT (Filed With SEC on March 15, 2016)
- STOCK PURCHASE AGREEMENT (Filed With SEC on September 1, 2015)
- Subscription Agent Agreement, dated February 25, 2015, by and between Opexa Therapeutics, Inc. and Continental Stock Transfer & Trust Company (Filed With SEC on May 12, 2015)
- Warrant Agreement, dated February 25, 2015, by and between Opexa Therapeutics, Inc. and Continental Stock Transfer & Trust Company (Filed With SEC on May 12, 2015)
- SUBSCRIPTION AGENT AGREEMENT [ ], 2015 (Filed With SEC on February 24, 2015)
- FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE (Filed With SEC on February 24, 2015)
